UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): December 15, 2014
(Exact Name of Registrant as Specified in Charter)
|
Nevada
|
333-155318
|
20-5337455
|
|
(State or other Jurisdiction
of Incorporation or
Organization)
|
(Commission File
Number)
|
(I.R.S. Employer
Identification No.)
|
3888 E. Mexico Ave., Suite 202
Denver, CO 80210
(Address of principal executive offices) (Zip Code)
(303) 309-0105
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On December 15, 2014, CannLabs, Inc. (the “Company”) hosted a corporate update conference call and webcast to provide investors with an update on recent corporate and business developments. A copy of the presentation utilized on the conference call and webcast is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The Company does not undertake to update this presentation.
The information contained in this Item 7.01 of this Current Report on Form 8-K and in the accompanying exhibit incorporated by reference herein shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. This information, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933.
Item 9.01 Financial Statements and Exhibits.
|
Exhibit No.
|
Description of Exhibit
|
| 99.1 |
Investor Presentation of CannLabs, Inc. dated December 15, 2014
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
CannLabs, Inc.
|
|
| |
|
|
|
|
Date: December 15, 2014
|
By:
|
/s/ Scott McPherson |
|
| |
|
Scott McPherson |
|
| |
|
Chief Financial Officer |
|
Exhibit 99.1
OTCQB: CANL
© CannLabs, Inc. – All rights reserved | 2 Overview Trading Statistics Price (as of 12/12/14) $0.92 Volume (3 month) 13,351 52 Week High/Low $2.43 /$0.85 Total Shares Outstanding 65.5M Float 13.9M % Insiders 79% Market Cap $56 M Other Headquarters Denver, CO Public Since June 12, 2014 Website www.cannlabs.com
© CannLabs, Inc. – All rights reserved | 3 Who Are W e? • CannLabs, Inc., is a respected authority and advisor to commercial, governmental and educational entities focused on the Cannabis industry. The company leverages its testing processes, propriety scientific, cloud - based business intelligence and data/analytics as well as consulting services to garner revenues from legalized Cannabis states and their constituents. • CannLabs customers include states that currently have legalized medical or recreational Cannabis along with their associated growers, dispensaries, manufacturers of edibles, and residential consumers seeking information on cannabis. • Through Carbon Bond Holdings Inc. and the state certified labs it has relationships with, CannLabs delivers best practices around products, services and business intelligence focused on the Cannabis industry.
© CannLabs, Inc. – All rights reserved | 4 Who Are We? • One of the pioneers and leaders • Four years running • One of the first licensed in CO, CT and NV • Multi - State Platform • Health and safety checkpoint in the seed to sale supply chain • Technology • Dedicated to maintaining the highest standards and equipment • Easily accessible test results from proprietary cloud - based technology with real - time analytics • Science - based methodologies • Reliable & scientifically validated results for growers and distributors • Credibility • Industry thought - leadership • Trusted consultants to growers, distributors & governments
© CannLabs, Inc. – All rights reserved | 5 Industry Dynamics • It’s a National Issue with increased consumer education leading to voter support • Currently there are 23 states approved for medical marijuana + D.C., and 4 states for recreation with 10 more currently in legislation • The medical and adult use marijuana segments will likely merge into one substantially larger market • New States are adopting more stringent guidelines which requires a larger suite of tests • Compliance & enforcement (i.e. fines, foregone revenues , loss of an entire grow) • Foremost underlying demand driver for growth is public health and safety • First inning of exponential growth • Proverbial “End of Prohibition” – Additional Information – Passed Legislation in 2014 Alaska - Oregon - Maryland – Minnesota – New York - D.C. States with Pending Medical Marijuana Legislation: Florida – Ohio – Pennsylvania States with Pending Legislation to Legalize Adult Use Cannabis: Rhode Island – Arizona – California – Delaware – Hawaii – Maine – Maryland – Massachusetts – Montana – New Hampshire – Nevada – Vermont Source: ProCon.org
© CannLabs, Inc. – All rights reserved | 6 Market Opportunity • Market expected to be $2.5 billion in 2014 with a 35% CAGR through 2018 ( CannaBuisnees Media: 2014) • Retail marijuana sales revenues could reach ~ $35 billion/year by 2020, if full legalization occurs in all 50 States and D.C. ( GreenWave Report: 2014) • Testing revenue will be approximately 2 - 3% of gross marijuana sales • Additional consulting revenue opportunities through new licensed growers U.S. Marijuana Sales Estimates 2013 - 2018 $ Billions $- $1.0 $2.0 $3.0 $4.0 $5.0 $6.0 $7.0 $8.0 2013 2014 2015 2016 2017 2018 Recreational Medical ©2014 CannaBusiness Media, a division of Anne Holland Ventures, Inc. All rights reserved
© CannLabs, Inc. – All rights reserved | 7 Cannabis Health & Safety • Potential for growers to inadvertently introduce unsafe cannabis products to consumers • Rapidly growing industry with expanding regulatory mandates: American Herbal Pharmacopoeia® (AHP) guidelines • Potency testing • Foreign material & microbial screening • Residual solvent testing • Aflatoxin testing • Pesticide testing • Heavy metal testing • Need for public health & safety for consumers and consistency for producers and distributors • CannLabs provides a comprehensive suite of testing methodologies coupled with consulting services on safe cultivation & production
© CannLabs, Inc. – All rights reserved | 8 Our Business Model • Immediate revenue growth achieved through testing • Lead generator into other higher margin revenue streams including consulting and product re - formulation • Large portfolio of test results (4 Years of data collected from 1000’s of tests) • Consultations • Solving production, cultivation & formulation challenges • Supplemented by data & analytics • Research & Development • MIP (Marijuana Infused Products) • Custom Formulations • Website monetization • Data & analytics allow growers & distributors to capture statistics over time • Consumers can locate desired products
© CannLabs, Inc. – All rights reserved | 9 Revenue & Growth Opportunity Drivers $ Revenue $ Sustained Growth Opportunities Current Mandated Testing (Potency, residual solvents, heavy metals, Aflatoxin , etc.) Advanced Testing (Food safety quality, genetics, control contamination, shelf life and storage ) Consulting (Cultivation advice, strain optimization, contamination issues) Research & Development (Reformulation, product advancement) Product Improvement Product Advancement Public Safety Commitment State & Legislation Driven
© CannLabs, Inc. – All rights reserved | 10 National Footprint • Colorado 4000 sq. ft. • Licences:496 Medical, 242 Recreational • Companies:225 (112 CANL) 49% share • Connecticut 4000 sq. ft. • 4 Commercial Licensed Growers • 2 Contracted with CANL 50% Share • Adheres to American Herbal Pharmacopoeia® (AHP) guidelines and United States Pharmacopeia guidelines • Nevada 8000 sq. ft. expected to open in third quarter of 2015 • Located in NV Cannabis Greenbelt neighboring 1.5 million sq. ft. of cannabis production • Adheres to American Herbal Pharmacopoeia® (AHP) guidelines
© CannLabs, Inc. – All rights reserved | 11 Investment Highlights • Sector and market are in infancy, exponential growth is anticipated (~$2.5B market estimated in 2014, growing at 35% CAGR) • Testing and services are needed and required ongoing • Health and safety checkpoint in the seed to sale supply chain • Replicable model as laboratory is the hub and ancillary services become the spokes – data, analytics & consulting create enhanced value • Expanding Nationwide footprint • Colorado – 4,000sq. ft. laboratory (April 2014) • Connecticut – 4,000sq. ft. laboratory (October 2014) • Nevada – 8,000 sq. ft. laboratory (Expected to open in spring of 2015) • The consumer wants access to safe products and information Our goal is to establish CannLabs as the preeminent testing laboratory and consultancy to the cannabis industry across the world
CannLabs (CE) (USOTC:CANL)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
CannLabs (CE) (USOTC:CANL)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
